Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Donate to our blog

Your support will help Science & Enterprise continue to provide science news for business people and business news for scientists.

Antibody Shows Promise Against Marburg Virus Infections

Tests with lab animals show an experimental synthetic antibody protects against deadly Marburg and Ravn viruses as long as 5 days following infections. . . . → Read More: Antibody Shows Promise Against Marburg Virus Infections

FDA Shown Approving New Drugs Faster than Europe

An analysis of regulatory actions in the U.S. and Europe, shows the U.S. Food and Drug Administration approves more new therapies and faster than the European Medicines Agency. . . . → Read More: FDA Shown Approving New Drugs Faster than Europe

Umbilical Cord Blood Evaluated for Autism Treatment

Results from a clinical trial show infusions of a child’s own umbilical cord blood are safe for treating autism spectrum disorder, and provide initial signs of effectiveness. . . . → Read More: Umbilical Cord Blood Evaluated for Autism Treatment

Prodrugs Designed to Better Target Cancer Therapies

A delivery mechanism is being developed to package cancer drugs in a nanoscale precursor state that reacts only in tumor regions, to protect against adverse effects. . . . → Read More: Prodrugs Designed to Better Target Cancer Therapies

Triple-Drug Inhaler Shown to Cut COPD Attacks

Results from a year-long clinical trial show that an inhaler with three types of drugs reduces the number of COPD attacks compared to a common single-drug inhaler. . . . → Read More: Triple-Drug Inhaler Shown to Cut COPD Attacks

Enhanced Gene Therapy Boosts Anti-Tumor Response

Gene therapies delivered with electronic pulses were shown in lab mice to increase production of natural immune-system proteins and reduce melanoma, or advanced skin cancer, tumors. . . . → Read More: Enhanced Gene Therapy Boosts Anti-Tumor Response

Zika DNA Vaccine Begins Clinical Trial

A new clinical trial is underway testing a Zika vaccine that uses genetically-engineered DNA to generate an immune response against the disease. . . . → Read More: Zika DNA Vaccine Begins Clinical Trial

Start-Up Licensing Flexible Genome-Editing Technology

A start-up biotechnology company is licensing techniques from two universities that make genome editing more flexible and better control gene expression. . . . → Read More: Start-Up Licensing Flexible Genome-Editing Technology

NIH Funds Seen Boosting Industry Patents

An analysis of grants issued by National Institutes of Health shows a large percentage of those grants, directly or indirectly, result in patented technologies in industry. . . . → Read More: NIH Funds Seen Boosting Industry Patents

CARB-X Commits $48M for Antibiotic Resistance R&D

A public-private partnership is spending $48 million in grants to biotechnology companies for research on treatments and diagnostics to counter antibiotic resistance, with half of that amount distributed immediately. . . . → Read More: CARB-X Commits $48M for Antibiotic Resistance R&D